Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.29 USD
Change Today +0.45 / 7.71%
Volume 549.7K
ANTH On Other Exchanges
As of 8:10 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

anthera pharmaceuticals inc (ANTH) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/24/15 - $11.65
52 Week Low
12/23/14 - $1.46
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

anthera pharmaceuticals inc (ANTH) Related Bloomberg News

View More Bloomberg News

anthera pharmaceuticals inc (ANTH) Related Businessweek News

No Related Businessweek News Found

anthera pharmaceuticals inc (ANTH) Details

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for patients with unmet medical needs. It is developing blisibimod, a Phase III product candidate that targets B-cell activating factor associated with various B-cell mediated autoimmune diseases, including systemic lupus erythematosus, Immunoglobulin A nephropathy, lupus nephritis, and others. The company is also developing a Phase III product candidate Liprotamase, a non-porcine investigational pancreatic enzyme replacement therapy intended for the treatment of patients with exocrine pancreatic insufficiency. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

20 Employees
Last Reported Date: 03/16/15
Founded in 2004

anthera pharmaceuticals inc (ANTH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $515.0K
Principal Accounting Officer, Compliance Offi...
Total Annual Compensation: $261.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $350.0K
Chief Technology Officer and Senior Vice Pres...
Total Annual Compensation: $340.0K
Chief Regulatory Officer and Senior Vice Pres...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

anthera pharmaceuticals inc (ANTH) Key Developments

Anthera Pharmaceuticals, Inc. Announces Initiation of the SOLUTION Clinical Study of Oral Sollpura (Liprotamase) Unit-Matched Therapy of Non-Porcine Origin in People with Cystic Fibrosis

Anthera Pharmaceuticals, Inc. announced the initiation of the SOLUTION (Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in People With Cystic Fibrosis) Phase 3 clinical study evaluating the efficacy and safety of Sollpura® (liprotamase), a microbial derived, biotech pancreatic enzyme replacement therapy (PERT), compared to an approved, porcine-derived, enteric-coated product for the treatment of exocrine pancreatic insufficiency (EPI). The Phase 3 SOLUTION clinical study is a multicenter, randomized, open-label, assessor-blind, non-inferiority, active-comparator study designed to evaluate the efficacy and safety of Sollpura in people with EPI due to cystic fibrosis. This pivotal study is intended to evaluate the non-inferiority of Sollpura compared with a commercially available PERT in a population enriched for PERT responders. The primary efficacy endpoint of this study will be comparative efficacy measured as the change in the coefficient of fat absorption (CFA) at the end of therapy. Results from the SOLUTION clinical study are anticipated to support marketing approval for Sollpura as a treatment for exocrine pancreatic insufficiency.

Anthera Announces Termination of Blisibimod Partnership in Japan by Zenyaku

Anthera Pharmaceuticals, Inc. announced receipt of a termination notice from its development partner in Japan, Zenyaku, terminating the December 2014 Collaboration and License Agreement (the License Agreement") effective January 7, 2016. The termination was at will" and alleged no breach of the License Agreement by Anthera. At the time of the notification, no patients had been enrolled in any blisibimod clinical studies in the Zenyaku territory and Zenyaku had not purchased any blisibimod product from Anthera.

Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Anthera Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company's total revenues were $289,000. Loss from operations was $8,846,000 compared to $6,865,000 a year ago. Net loss was $8,895,000 compared to $7,256,000 a year ago. Net loss per share attributable to common stockholders - basic and diluted was $0.25 compared to $0.34 a year ago. For the six months, the company's total revenues were $534,000. Loss from operations was $16,503,000 compared to $14,474,000 a year ago. Net loss was $16,555,000 compared to $15,172,000 a year ago. Net loss per share attributable to common stockholders - basic and diluted was $0.52 compared to $0.73 a year ago. The increase in net loss both quarterly and year-to-date is mainly driven by higher clinical development expense for blisibimod program and manufacturing and study preparation expenses for the Sollpura development program.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANTH:US $6.29 USD +0.45

ANTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ANTH.
View Industry Companies

Industry Analysis


Industry Average

Valuation ANTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 421.9x
Price/Book 8.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 401.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANTHERA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at